Navigation Links
Scientists remove amyloid plaques from brains of live animals with Alzheimer's disease
Date:10/15/2009

A breakthrough discovery by scientists from the Mayo Clinic in Jacksonville, FL, may lead to a new treatment for Alzheimer's Disease that actually removes amyloid plaquesconsidered a hallmark of the diseasefrom patients' brains. This discovery, published online in The FASEB Journal (http://www.fasebj.org), is based on the unexpected finding that when the brain's immune cells (microglia) are activated by the interleukin-6 protein (IL-6), they actually remove plaques instead of causing them or making them worse. The research was performed in a model of Alzheimer's disease established in mice.

"Our study highlights the notion that manipulating the brain's immune response could be translated into clinically tolerated regimens for the treatment of neurodegenerative diseases," said Pritam Das, co-author of the study, from the Mayo Clinic in Jacksonville, FL.

Das and colleagues made this unexpected discovery when they initially set out to prove that the activation of microgila trigger inflammation, making the disease worse. Their hypothesis was that microglia would attempt to remove the plaques, but would be unable to do so, and in the process cause excessive inflammation. To the surprise of the researchers, when microglia were activated by IL-6, they cleared the plaques from the brains.

To do this, the researchers over-expressed IL-6 in the brains of newborn mice that had yet to develop any amyloid plaques, as well in mice with pre-existing plaques. Using somatic brain transgenesis technology, scientists analyzed the effect of IL-6 on brain neuro-inflammation and plaque deposition. In both groups of mice, the presence of IL-6 lead to the clearance of amyloid plaques from the brain. Researchers then set out to determine exactly how IL-6 worked to clear the plaques and discovered that the inflammation induced by IL-6 directed the microglia to express proteins that removed the plaques. This research suggests that manipulating the brain's own immune cells through inflammatory mediators could lead to new therapeutic approaches for the treatment of neurodegenerative diseases, particularly Alzheimer's disease.

"This model is as close to human pathology as animal models get. These results give us an exciting lead to newer, more effective treatments of Alzheimer's disease," said Gerald Weissmann, M.D., Editor-in-Chief of The FASEB Journal. "This study demonstrates that investment in experimental biology is the best way to approach the challenge posed by an aging population to the cost of health care."


'/>"/>

Contact: Cody Mooneyhan
cmooneyhan@faseb.org
301-634-7104
Federation of American Societies for Experimental Biology
Source:Eurekalert

Related biology news :

1. UNC scientists win $1.6 million stimulus award to accelerate decoding of human genome
2. Scientists urge EPA to adopt systems thinking
3. Scientists identify common HPV genotypes in northern India, encourage vaccination
4. Scientists take step toward simple and portable tuberculosis tests for developing world
5. Too much of a good thing? Scientists explain cellular effects of vitamin A overdose and deficiency
6. MDC scientists show how hematopoietic stem cell development is regulated
7. You must remember this: Scientists develop nasal spray that improves memory
8. Scientists discover clues to what makes human muscle age
9. Stimulus-funded university research addressing issues from climate change to cancer, creating jobs and training a new generation of scientists
10. Scientists join forces to explain HIV spread in Central and East Africa
11. Chinas new Climate Center welcomes citizen scientists
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2017)... 2017  Aware, Inc. (NASDAQ: AWRE ), a ... results for its quarter and year ended December 31, 2016. ... was $3.9 million compared to $6.9 million in the same ... 2016 was $0.6 million compared to $2.6 million in the ... of 2016 was $0.5 million, or $0.02 per diluted share, ...
(Date:2/7/2017)... , Feb. 7, 2017 Zimmer Biomet ... in musculoskeletal healthcare, will present at the LEERINK Partners ... York Palace Hotel on Wednesday, February 15, 2017 at ... webcast of the presentation can be accessed at ... following the conference via Zimmer Biomet,s Investor Relations website ...
(Date:2/2/2017)... 2017   TapImmune, Inc. (NASDAQ: ... in the development of innovative peptide and gene-based ... and metastatic disease, announced today it has successfully ... a second clinical lot of TPIV 200, the ... The manufactured vaccine product will be used to ...
Breaking Biology News(10 mins):
(Date:2/24/2017)... China Biologic Products, Inc. (NASDAQ: CBPO) ("China Biologic" or the ... today announced its financial results for the fourth quarter and ... Financial Highlights Total sales in the ... or increased by 13.6% in USD terms to $77.6 million ... Gross profit increased by 13.3% to $46.8 million ...
(Date:2/23/2017)... and NEW YORK , ... Lumeon , a leading digital health company, ... a provider of telemedicine and remote patient monitoring, ... for telemedicine reimbursements.  DN Telehealth ... patients, in real-time, extending consultations beyond a physical ...
(Date:2/23/2017)... TORONTO , Feb. 23, 2017 /PRNewswire/ - The ... Institute for Cancer Research (OICR) are pleased to report ... Series A financing, with Johnson & Johnson Innovation – ... investors include venture groups HealthCap, TPG Biotechnology Partners, and ... ...
(Date:2/23/2017)... SEATTLE , Feb. 23, 2017  Seattle,s upscale Capitol ... like a strange place for a head lice treatment salon ... nestled between a Tuscan restaurant and a French bistro on ... it,s perfect. "We aren,t just any old lice clinic, we ... to feel comfortable, and release some of the stigma associated ...
Breaking Biology Technology: